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Summary.-Immunoglobulin (Fc) receptors were detected on leucocytes from
patients with acute myeloid leukaemia (AML) by rosette formation with human
cDE/cDE erthyrocytes (HE) sensitized with Rhesus (Rh) antisera (HEA). Of 7 Rh
antisera tested, erythrocytes sensitized with anti-D (Gm10) detected the highest
numbers ofrosette-forming cells (HEA-RFC) innormal and AMLleucocyte prepara-
tions. Using this assay, HEA-RFC was studied in 22 untreated AML patients and
compared withresultsfrom 11 normalindividuals, and otherleukaemias. The assay
detected 11.6% lymphocyte and 2.1% granulocyte HEA-RFC in normal peripheral
blood. Leucocytes from 16 of the 22 AML patients had a similar orlower percentage
than normal lymphocyte HEA-RFC, which could be explained by the dilution of
peripheral blood leucocytes bypoorlyor non-rosetting leukaemic blasts. Ten ofthese
16 patients were diagnosed as having acute myeloblastic leukaemia. Six of the 22
AML patients had high HEA-RFC values of which 5 were diagnosed as having
myelomonocytic leukaemia. Cytocentrifuge preparations of HEA-RFC showed that
the proportion able to form rosettes was lower in myeloblasts than in monoblasts.
Enzyme treatment (pronase), inhibition or simultaneous labelling of surface Ig and
Fc receptors showed that the characteristic surface Ig found on AML cells is, at least
in part, bound to Fc receptors. The HEA-RFC test described in this paper could be
useful in the immuno-diagnosis of myelomonocytic leukaemia.
Receptors for human IgG have been
demonstrated on human leucocytes inclu-
ding monocytes (Huber and Fudenberg,
1968, Abramsonetal., 1970a),polymorpho-
nuclear neutrophils (Messner and Jelinek,
1970) and a subpopulation oflymphocytes
(Brain and Marston, 1973; Fr0land et al.,
1974a). Thatthereceptorrecognizes the Fc
fragment ofIgG has been demonstrated by
the inhibition of IgG binding to cells by
isolated Fc but not Fab or F(ab')2 frag-
ments (Abramson et al., 1970b; Messner
and Jelinek, 1970; Fr0land et al., 1974a).
Although Fc receptors are important for
thephagocytosis ofantigen-antibody com-
plexes by monocytes and macrophages,
(Huber and Fudenberg, 1968, Huber,
Douglas and Fudenberg, 1969) and in
antibody-dependentlymphocyte-mediated
cytotoxicity (Dickler, 1974; Wisl0ff,
Fr0land and Michaelson, 1974) the func-
tional significance of Fc receptors in vivo
still remains unclear. Nevertheless, Fc
receptors are to be found on many cell
types, both phagocytic and non-phago-
cytic, involved in the immune response.
We have observed, as have Gutterman
et al. (1973) that cells from patients with
acute myeloid leukaemia (AML)* often
have a characteristic stainingpatternwhen
reacted with fluorescein-conjugated anti-
human Ig. This irregular and patchy
staining is similar to that seen when
aggregated IgG bound to lymphocyte Fc
receptors is stained with an anti-immuno-
globulin fluorescent conjugate (Dickler
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and Kunkel, 1972; Dickler, 1974). Like
lymphocyte-bound aggregated IgG, but
unlike lymphocyte surface Ig, AML-Ig can
be capped only with difficulty or not at all
(unpublished observations). This appar-
ent similarity in the appearance and
behaviour oflymphocyte-bound and AML-
bound Ig led us to investigate whether
AML cells also have Fe receptors. We
used as indicator cells for Fc receptors,
anti-Rhesus antibody-coated human ery-
throcytes. The results show that a
number ofpatients, diagnosed on the basis
of bone marrow cytology as acute myelo-
monocytic leukaemia (AMML) have large
numbers ofFe receptor-bearing cells in the
peripheral blood. Proteolytic enzyme or
serum treatment of the AML cells show
that these receptors can be further un-
masked or blocked respectively, suggest-
ing that at least part of the AML surface
Ig is bound in vivo to Fc receptors. The
results in this paper also show that the
relatively rapid rosette test described
could be useful in the diagnosis of AMML
using peripheral blood leucocytes, as an
adjunct to conventional bone marrow
diagnosis.
MATERIALS AND METHODS
Nlormal and AML leucocyte separations.-
Venous blood from healthy adults and from
untreated adult AML patients was anti-
coagulated with heparin (10 iu/ml) or by
defibrination. Whole blood total white cell
counts were performed on a Coulter Model
"5 " cell counter and differential cell counts
were made using Romanowsky-stained blood
smears. The blood was diluted 1: 1 with
saline and layered on to a mixture of Ficoll
(Pharmacia, Uppsala, Sweden) and Triosil
(Nyegaard, Oslo, Norway), centrifuged at
400g for40 min at4° C (Boyum, 1968) and the
leucocyte-enriched interface between the
Ficoll/Triosil and plasma collected. The cells
in this layer were then washed three times by
centrifugation in Hanks' balanced salt solu-
tion (HBSS) before further use. The Ficoll/
Triosil sedimented leucocytes were collected
by resuspending the Ficoll/Triosil sedimented
mixture of erythrocytes and leucocytes in
2 ml of supernatant plasma and 0-4 ml of 4.5% Dextran (Pharmacia, Uppsala, Sweden).
The erythrocytes were sedimented at 4°C for
approximately 30 min at 1 q, after which the
leucocytes in the supernatant were removed
and washed three times by centrifugation in
HBSS. Smears of the cell separations wAere
made on slides, stained with Romanowsky
stain and differential cell counts made.
Other leukaemias and cell lines-.Peri-
pheral blood leucocytes were obtained from
chronic lymphocytic (CLL) acute lympho-
blastic (ALL) and chronic myeloid (CML)
leukaemie patients with high leucocyte
counts. The leucocytes were separated on
Ficoll/Triosil as above.
The two lymphoblastoid cell lines (BR18
and MICH) were obtained from Searle
Laboratories, High Wycombe, and cultured
in RPMI-1640 (Flow Laboratories, Scotland)
containing 10% FCS.
Human erythrocytes and Rh antisera.
Human eDE/eDE (R2R2) erythrocytes (HE)
from a single donor were collected into acid-
citrate-dextrose solution and stored at 4°C
for no longer than 1 month. Sera containing
Rh antibody (Biotest, Folex, Birmingham,
U.K.) in some cases of known Gm allotype
were titrated against the HE, using thedirect
(saline) and indirect (Coombs) agglutination
techniques. Of the 7 sera used, 2 (anti-D
and anti-CDE) had complete and incomplete
antibodies, whilst the other 5 had incomplete
antibodies only. The highest dilution of Rh
antiserum which gave the strongest indirect
agglutination and no direct agglutination was
selected for each serum as followNs: anti-D,
anti-CD, anti-CDE, all at 1/32; anti-D (Gm')
1/100; anti-D (Gm2) 1/200; anti-D (Gm10)
and anti-D (Inv'), both at 1/400.
Sensitization oferythrocytes.-Sensitization
of HE for rosette assays and Gm typing was
carried out by mixing equal volumes of
appropriately diluted Rh antiserum with a
20% suspension of cDE/cDE erythrocytes at
37°C for 30 min, followed by three washes in
phosphate-buffered saline (PBS). The anti-
body-coated erythrocytes (HEA) were re-
suspended in PBS at a concentration of
5 x 107/ml.
Rosette-forming cell(RFC) assay.-Aliquots
(3 x 106/ml) of the interface or sedimented
cell suspensions were mixed with an equal
volume of HEA in 13 x 76 mm plastic tubes.
The mixtures were incubated at 20°C for
30 min, centrifuged at 200 g for 5 min and
resuspended by gently tapping the tubes.
Two drops of 0.2% methylene blue in saline
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were added to each cell suspension to stain
the nucleated cells, and a single drop of this
suspension was placed on a microscope slide.
Rosetted cells were counted under bright
field illumination, and the numbers expressed
as a percentage of the total number of
nucleated cells counted (300 +). A rosette
was defined as a leucocyte surrounded by
three or more HEA. In some cases cyto-
centrifuge preparations of rosetted cells were
made and stained with Romanowsky stain.
Enzyme treatment of leucocytes.-Equal
volumes (01 ml) of leucocytes (6 x 106/ml)
and each ofthefollowing enzyme preparations
in HBSS were incubated at 37°C for the
following times: pronase (protease type VI,
Sigma, London), 1 mg/ml-10 min; papain
(Sigma, London), 1 mg/ml-10 min and
trypsin (Wellcome Laboratories, Beckenham,
Kent), 0-25 mg/ml-5 min. The enzyme-
treated leucocytes were then washed three
times in HBSS, resuspended at a concen-
tration of 3 x 106/ml and rosetted with
HEA.
HEA-rosette inhibition.-Leucocytes (6 x
106/ml) from the interface ofseparated normal
or AML blood were incubated for 30 min at
37°C with an equal volume (0.1 ml) of the
following: normal AB or pretreatment AML
serum centrifuged at 70,000 g for 5 h and
separated into supernatant (deaggregated)
and pellet fractions; human gamma-globulin
(Cohn Fraction II, Sigma) or human albumin
(Cohn Fraction V, Sigma), the latter two at
concentrations of 1 mg/ml. The leucocytes
were then washed by centrifugation three
times in HBSS, resuspended at 3 x 106/ml
and rosetted with HEA as previously
described.
Membrane immunofuorescence.-AML
leucocytes, with or without prior pronase
treatment, were incubated with 1/10 dilution
of sheep anti-human immunoglobulin-FITC
conjugate (SaHIg-FITC, Wellcome Labora-
tories, Beckenham, Kent) at 4°C for 30 min.
The leucocytes wrere washed three times with
HBSS and rosetted with HEA, suspended in
PBS, and each cell examined under alternate
dark field u.v. light for fluorescing cells and
bright field phase contrast for rosetted cells.
These cells were classified either as rosetting
but not staining (RFC + Ig-), non-rosetting
but staining (RFC - Ig +, or those both
rosetting and staining (RFC + Ig +).
RESULTS
Optimum HEA-RFC technique
The optimum method for HEA rosette
formation with AML and normal leuco-
cytes, was found to be 30 min incubation
at 20°C, followed by centrifugation at 200g
for 5 min. Centrifuging cells prior to
incubation did not affect the results, but
incubation at 37°C gave lower values.
The source of the Rh antisera used to
sensitize the cDE/cDE erythrocytes, was
found to be particularly important. In
Table 1 results are shown for leucocytes
from 5 normal individuals and 2 AMML
patients when tested for HEA with
erythrocytes coated with different anti-
Rhesus antibodies.
Anti-D (Gm10) sensitized cDE/cDE
erythrocytes gave consistently higher
values than the other sensitizing sera.
Note also the higher RFC values obtained
with the AMML (case 15) compared with
normal leucocytes. Two anti-D (Gm10)
sera from different donors were used to
sensitize different batches ofHE, and were
found to give comparable results (not
shown). The Gm allotypes of the Rh
antisera were determined by direct
agglutination ofHEAwith anti-Gm typing
TABLE I.- Rosette Formation by Normal and AML Leucocytes with HE sentisized with
Different Anti-rhesus Sera
% leucocytes forming rosettes with HE sensitized with:t-\~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Peripheral blood Ficoll/Triosil
leucocytes from: fraction
Normalt Interface
AMML (15)* Interface
?AMML (I 8)* Interface
* Case Nos. from Table II.
t All sera from Biotest Folex U.K.
t Average of tests on 5 normals.
Anti-D
Anti-D Anti-CD Anti-CDE (Gm')
:3-3 2-8 5 ,3 3 9
8-8 5-6 38-7 8-7
3-3 6 2 7-2 1.0
Anti-D
(Gm2)
3 -2
9-6
1 7
Anti-D
(Gm10)
13-0
43 -2
11*1
Anti-D
(Inv')
10-8
34-5
5-2
348Fc RECEPTORS ON AML LEUCOCYTES I
0 ~ ~ ~ ~ ~ ~ ~~~0
0
00Cot . 000 0 1-t.1010
-P4 c00iCt 01X0
t
I -W- -H
Io X 000 oI,O t Co' J4CO00 o o o t
0 o _0 ' 1 0 010 010>o;
I> 1> -s o> liii
10
X co0oorsooio0c0s0000010 0t00Cccei01co t
- 0_ _ 10 --H
0
0 o oo oo o o o co o o o 0 0 o o la o
S- 000 000to00-I00t 000-N 0000
0)00qQa Oa n 10t-cmo ~0 o 0 Mt
4
01000 o 00 oc C0o00 0000000 101000"- aqmmi Co 1000000t 10 "CoC -41 E -4 " 00
000 0-01 = _ _ 0oot laCo000' 0 0o CO
-X 00 s es 00 -- e CD4 N M b --
10001 00 00 01_q000 _0i C C e0_
01cq c00 Co01C'1q a 00 CoCo0t- ~ 1 00 co
~~~~~~~~~~~IL 0~~~~~~~~~~~~~~~~~
CO 4
1. 1
,-q 0
O 114 d
pJ pi
¢4 ¢4 ¢ ¢4
11 .-i I
0
0 i 0 14--J
.4 .4 .-4 .. 0
h-r-4 .4 .4 IC$
.-4 , .i -
4 P4 4 4 .4x X X 0-.4 4
,I x u .-,
-.-, 4 4 4 X X .! .21
G. q-. ---. --. .!4 u u --!. 0 0 u T-)
6
z
C1)I
0 q , o=1 qM4 a -m=o- qm"Li=t
- 4 P 4 - 4 - - - ~-4
349
I
C2) .
10
4)
C)
C)
-Q
0
C)1 Ca T$
C)
t
lt ._.
M
0-1-
-4
ea
?Z .-
*_s
C0
cD
V.)
V
d
P ,o
^ A,
0
Pe 0
o
C1)
,ZP4
9 C)
0
V.)
r r - m
0
.J. C. RIDWAY, G. M. TAYLOR, C. B. FREEMAN AND R. HARRIS
sera. Only the anti-D (Gm10) and the
anti-CDE sera reacted with anti-Gm10
serum. The significance of this reaction
is discussed later.
In further tests (data not shown), HE
of different Rhesus phenotypes were
sensitized with Anti-D (Gm'0) antiserum
and tested with 4 different AMML cells.
The percentage RFC obtained was lower
when d/D rather than D/D indicator cells
were used in the RFC assay. Moreover,
the presence of the C phenotype reduced
the number of RFC. Maximum numbers
of RFC were found with cDE/cDE
erythrocytes, and no RFC were detected
using unsensitized cDE/cDE erythrocytes,
or anti-D (Gm10) treated cde/cde erythro-
cytes.
Rosette formation by normal and AML
leucocytes
Using anti-D (Gm10) sensitized cDE/
cDE erythrocytes as indicator cells, recep-
tors for human Ig were investigated on
leucocytes from 11 normal individuals,
22 with untreated acute myeloid leukae-
mia, 2with chroniclymphocyticleukaemia,
4 with chronic myeloid leukaemia, and
one with adult lymphoblastic leukaemia.
The results are depicted in Table II. The
diagnoses, which in the case of the
myeloid leukaemias were established by
the examination of Romanowsky-stained
bone marrow smears in the Department of
Clinical Haematology, at the Manchester
Royal Infirmary, were in most cases un-
known to us at the time that peripheral
blood leucocytes were assayed for HEA-
RFC. The differential cell counts were
performed in our own laboratory on the
blood samples subsequently separated on
Ficoll/Triosil, and in a number of cases
differential counts were performed on the
cells obtained after Ficoll/Triosil separa-
tion.
Blasts from the AML cell separations
were found to accumulate mainly in the
interface fraction, unless the peripheral
leucocyte count was greater than 5 x 104/
mm3, in which case they were carried over
into the sedimented fraction. In the
majority of cases examined after Ficoll/
Triosil separation, there was an increase
in the proportion of blasts in the interface
fraction compared with the unseparated
cells. In the 5 preparations ofsedimented
cells examined, nucleated cells other than
blasts comprised the majority of cells.
Ficoll/Triosil separation is a method
principally for separating lymphocytes
from polymorphonuclear neutrophils (also
referred to in this paper as " granulo-
cytes ") and erythrocytes. To define the
number of HEA-RFC in these two leuco-
cyte fractions, results of 11 separations of
normal leucocytes are shown. Nine of
the 11 interface separations contained
80% or more (mean 84%) lymphocytes,
most of the other cells being granulocytes,
whilst all 11 Ficoll/Triosil-sedimented
leucocytes contained 750O or more (mean
95-8%o) granulocytes, both fractions being
assessed by differential counting of Roma-
nowsky-stained smears.
The normal leucocyte fractions were
rosetted to establish an HEA-RFC base-
line with which to compare AML HEA-
RFC values. If greater percentages of
RFC are found in AML peripheral leuco-
cyte preparations, compared with normal
leucocytes, this could be taken to indicate
the participation of AML cells in rosette
formation, whilst any decrease in AML
RFC compared with normal could mean
the dilution of normal RFC by non-
rosetting leukaemic leucocytes. In agree-
ment with Table I, interface normal
leucocytes had greater numbers of RFC
(11-64 + 4.24%) than the sedimented
granulocytes (2.15 1.22%) separated
from the same blood sample (Table II).
Sixteen of the 22 cases of AML had RFC
values within or lower than the normal
interfacerange. Inmost caseswherethere
was a high percentage of myeloblasts and
a very low number of RFC (Cases 5, 7, 8,
12 and 20) myeloblasts were not likely on
numerical grounds to be forming rosettes.
In other cases, (1, 4, 6, 9, 11, 14 and 18)
where the RFC values approximate to the
"normal", the unseparated and separated
cells contained relatively high percentages
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of myeloblasts. This could mean, either
that all or most ofthe lymphocytes present
in these patients were of the minor sub-
population found in normals bearing Fe
receptors, or more likely that a small
number of other nucleated cells, including
myeloblasts were HEA-RFC. It is not
possible to distinguish between these two
possibilities. Nevertheless, 8 of the 12
cases with relatively low numbers of RFC,
but with relatively high numbers of blasts
described above, were diagnosed as acute
myeloblastic leukaemia.
Six AML cases had conspicuously high
numbers of RFC (cases 10, 15, 16, 17, 19
and 21) of which 3 (15, 16 and 19) were
confirmed, and 1 (17) was suspected AMML
by bone marrow examination. Case 21
was one ofchronicmyelomonocytic leukae-
mia in blast crisis. Two cases (1]5 and 19)
had no significant monoblastic, monocytic
or promonocytic component in the peri-
pheral blood assessed by cytological exami-
nation, whereas cases 16, 17 and 21 had a
high proportion of mixed monoblasts and
promonocytes and fewer myeloblasts.
Further details of cases 17, 19 and 21 are
presented below. Case 10, which had
abnormal myeloblasts in the bone marrow,
was diagnosed as a " vacuolated pro-
monocytic" AML.
Fourteen sedimented AML leucocyte
fractions were tested and 3 (16, 17 and 19)
had high numbers of HEA-RFC similar to
those in the interface ofthe same prepara-
tion. In the remaining cases, the HEA-
RFC values were similar to or lower than
those found in the interface fraction.
One case tested, of atypical monocytic
leukaemia (22), did not have the large
numbers of HEA-RFC which might have
been expected from the diagnosis and the
peripheral blood differential count.
The CLLs, CMLs and the ALL all had
HEA-RFC values lower than "normal",
although in real terms the numbers of
HEA-RFC were high in CML peripheral
blood.
Cytology of HEA-RFC
Rosetted AML leucocytes were identi-
fied in Romanowsky-stained cytocentri-
fuge preparations. Many of the prepara-
tions proved equivocal, because of the
tendency of rosetted leucocytes to con-
dense and " overstain ", and the presence
of false rosettes caused by clustering of
HE around leucocytes during drying.
However, 5 preparations were made where
these problems were not encountered, and
the results are shown in Table III.
The smouldering leukaemia (Case No.
11) had predominantly myelocyte HEA-
RFC in the interface fraction, though 10%
of the RFC were myeloblasts. The sedi-
mented cells had predominantly granulo-
cyte RFC, with 30% myelocyte RFC, but
no myeloblast RFC. Cases 17 and 18,
both diagnosed by bone marrow exami-
nation, as probable AMML, differed in the
numbers of HEA-RFC in the peripheral
blood (see Table II). In case 17, with 63%
HEA-RFC in the interface and 68% HEA-
RFC in the sediment, most of the rosetted
cells were monocytic in appearance (Table
III), though 40%o of the sedimented RFC
were granulocytes. No myeloblast RFC
were seen in this preparation, which is not
TABLE III.-Cytology of Rosetted AML Leucocytes
% HEA-RFC identified as:*
Ficoll/Triosil M +
Ise No. Diagnosis* fraction L N MoBI M
Smould. AML Initerface 0 5 0 5
Sediment 0 70 0 3(
?AMML Interface 0 0 70
Secdiment 0 40 60
?AMML Interface 0 0 0
AMML Interface 6 0 10
ACMML Interface 0 0 62
* Abbreviations and case numbers as in Table II. Unident: unidentifiable.
ly
5
0
9
9 0 LI
LI
Ca
11
17
18
1 9
21
MyBI
10
0
0
0
100
83
38
Uniclent
30
0
30
0
0
1
0
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surprising, since myeloblasts were only
identified as 20% of the peripheral blood
leucocytes in the unseparated sample.
Case 18 was quite different, since mono-
cytic cells were a very small percentage,
and myeloblasts a high percentage, of the
unseparated peripheral blood leucocytes.
The HEA-RFC in the interface (11.1%;
Table II) were all myeloblasts (Table III).
Since 860o of the interface cells were
myeloblasts, of which 11% were rosetted,
about 7000 of the myeloblasts did not
form rosettes using the HEA-RFC assay.
Case 19, a confirmed AMML, had
59.2% HEA-RFC (Table II) most ofwhich
proved to be myeloblasts in the cyto-
centrifuge preparations (83%; Table III).
Case 21, that ofACMML, had a mixture of
nearly twice as many monocytic RFC as
myeloblastic RFC.
Effect of enzymes on HEA-RFC
To investigate whether rosetting could
be increased by theremoval ofFe receptor-
bound immunoglobulin, the effect of
proteolytic enzymes on normal and AML
leucocytes was compared in the following
experiments. Preliminary tests had
shownthat concentrations oftrypsin above
0.25 mg/ml reduced the HEA-RFC in
normal leucocyte preparations. Normal
and AML leucocytes were thus incubated
for 5 min at 37°C in 0-25 mg/ml trypsin in
HBSS, and in similar experiments for 10
min at 37°C in 1 mg/ml papain or 1 mg/ml
pronase in HBSS. The results in Table
IV show that interface leucocytes from
normalindividualsshowedaslightdecrease
in RFC after proteolytic enzyme treat-
ment, particularly papain, whilst normal
sedimented granulocytes showed a small
increase in RFC.
Interface leucocytes from 6/8 and
sedimented leucocytes from 3/5 AML
patients showed a marked increase in
HEA-RFC following treatment with pro-
teolytic enzymes, particularly after pro-
nase and to a lesser extent papain. This
increase was most marked in case 16, an
AMML with a low percentage of myelo-
blasts, but a high percentage of mono-
blasts/promonocytes, and was much less
apparent, or non-existent, in the enzyme-
treated acute myeloblastic leukaemias.
The case of ACMML (Case 21) showed a
decrease in RFC numbers after pronase
treatment, whilst one ofacute monoblastic
TABLE IV.-Effect ofProteolytic Enzymes on AML HEA-RFC
% ofHEA-RFC following treatment with:
Case No.* Diagnosis
5 AML
6 AML
8 Erythro.AML
11 Smould.AML
Smould.AML
12 AMML
16 AMML
21 ACMML
A.Mono.L.
CLL
ALL
- BRI8}X
MIICHf§
Normalt
(n= 7)
* Case nos. as Table II.
t Mean values ± S.D.
+ -not tested.
§ Lymphoblastoid cell lines.
Ficoll/Triosil
fraction
Interface
Sediment
Interface
Sediment
Interface
Interface
Sediment
Interface
Interface
Interface
Interface
Sediment
Interface
HBSS
4-5
1*0
10*0
5-0
2-0
15-0
16-0
6-0
0
27-8
50-0
7-0
2-7
0
0-3
0
Interface 13 1 +5 9
Sedliment 2-9 2-2
Pronase Papain
7-6 10 7
7-6
2-7 4-0
2-7 2-0
2-0 2-,3
26-0
29-6
8-0
4-7
50 3
39-8
4-3
17-3
0
0-3
0
9-2 + 7-4
5-2 ± 4-2
6-0
2-6
20-7
14-5
0
0-6
0
257- 2 1
Trypsin
2-0
0-3
1-7
16-0
23-7
4-2
5.3
5.3
0
0
80i6-
30-X3
3-1+ 3 1
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leukaemia, not included in the series in
Table II, showed a marked increase in
RFC after pronase and papain. None of
the cell lines or other leukaemias tested
showed any significant increase in RFC
after enzymes, and parallel tests (not
shown) showed that enzyme-treated AML
leucocytes were unable to rosette with
unsensitized HE, showing that enzymes
unblocked (or in some cases destroyed) Fc
receptors.
Relationship between surface Ig and HEA-
RFC
The relationship between Ig-bearing
and HEA-rosetting AML cells was in-
vestigated, using a double labelling tech-
nique. Leucocytes from the bone marrow
of Case 11 and the peripheral blood from
Case 21 and an additional case of AML,
were treated with pronase or left un-
treated, and then stained with SaHIg-
FITC and rosetted with HEA. Cells
from each preparation were examined for
rosetting only (RFC+Jg-), for immuno-
fluorescent staining only (RFC-Jg+) or for
simultaneous staining androsetting (RFC+
Ig+). Following pronase treatment, leuco-
cytes from two of the patients showed a
marked increase in the percentage of
double labelled (RFC+Jg+) cells whilst
there was a marked decrease in the per-
centage of non-rosetting, anti-immuno-
globulin-staining cells (RFC-Ig+) and very
little change in the number of rosetting
non-staining (RFC+Ig-) cells. In the
third case there was a high percentage of
RFC-Ig+ cells and no RFC+lg- cells
prior to pronase treatment. After treat-
ment, most of the cells were found to be
RFC+lg-, with a marked decrease in
RFC-Ig+ cells.
Inhibition ofHEA-RFC
Normal AML HEA-RFC were found
to be markedly inhibited if they were
TABLE V.-Effect ofPronase on HEA-RFC and Surface Ig ofAML Leucocytes
% Leucocytes identified as*
Pronase , -
Case No.t Diagnosis Treatment RFC+Ig+ RFC+Ig- RFC-Jg+
11 Smould.AML 4-0 60 0 36 0
(BM)l + 58-0 42 0 0 21 ACMML (PBL) - 1115 20 5 68 0
+ 57*0 15.0 28 0 - AAML (PBL) - 20 0 0 80 0
+ 26 0 56-0 18 0
* RFC+ = HEA-RFC. RFC- = no HEA-RFC. Ig+ = cells staining with SaHIg-FITC. Ig- cells
not staining.
t Case Nos. as in Table II.
t BM = bone marrow leucocytes separated by dextran sedimentation.
PBL - peripheral blood interface leucocytes.
TABLE VI.-Inhibition ofHEA-RFC by AML and Normal Serum
% HEA-RFC following treatment of interface leucocytes with:*
Serum
Case No.t Diagnosis Hanks'
BSS
AML 10 0
10 Atyp.AML. 28 -0
16 AMML 27-8
A.Mon.L. 34-3
AMML 39 -6
Normal 24*0
Normal 9*0
Autologous
1-3 (87)
17-0 (40)
1 - 7 (93 9)
3-3 (90 4)
3 -0 (92 5)
1-3 (94 6)
AB
0-8 (92)
14-0 (50)
7-3 (74)
4 0 (90)
1-7 (93)
1-9 (79)
AML
0
8-
* Figures in parentheses indicate % inhibition of HEA-RFC (see Table VII).
t Case Nos. as in Table II.
$ Values for three different allogeneic sera.
*7 (97),0 5 (98), 0 (100)t
*0 (12),3-4 (63),5-1 (44)
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TABLE VII.-Inhibition of HEA-RFC by aggregated and de-aggregated serum fractions,
y-globulin and albumin
Case No.t
17
19
21
Diagnosis
AMML
AMML
ACMML
Normal
Normal
Normal
% Inhibition of HEA-RFC interface leucocytes following treatment with:§
AML Serum: AB Serumt Human Human
-a - - , y-globulin Albumin
Supernataint Pellet Supernatant Pellet (1 mg/ml) (1 mg/ml)
83-4* 95 0 81-6 100 96-5 0
94 9 78-2 81-2 66 92-8 0
91.3* 92-3 97 0 100 97-0 71-3
100 75-6 89-1 56-7 86-4 24-3
26 5 41-7 32-9 2-5 55-6 20-2
90 8 95-4 71-2 66-6 100 0
* Autologous AML serum.
t Case Nos. as in Table II.
t Sera separate(l into supernatant and pellet following 75,000 g for 5 h.
100 HEA-RFC in inhibitor x 100 § Results expressed as 100 0 HEA-RFC in HBSS
incubated either in autologous, AB or
allogeneic AML serum, then washed 3
times in HBSS and rosetted with HEA
(Table VI). Inhibition could not have
been caused by the agglutination of the
HEA, since all free serum was removed by
washing, prior to the rosette assay.
Further tests were carried out, using the
same assay, on AML and normalleucocytes
mixed with de-aggregated (supernatant) or
aggregated (pellet) fractions following
centrifugation of AML and AB serum for
5 h at 70,000 g (Table VII). Strong in-
hibition was found by both fractions, the
extent of the inhibition being greater with
AML cells tha,n with normal leucocytes.
Inhibition was also seen when normal and
AML leucocytes were tested with Cohn
fraction II gamma-globulin, though it was
less in the normal than in AML leucocytes.
Albumin (Cohn Fraction V) inhibited
HEA-RFC in one AML leucocyte prepara-
tion, but was ineffective in the other two,
and only slight inhibition was seen in 2 out
of 3 normal leucocyte preparations.
DISCUSSION
This study shows that receptors for
human immunoglobulin can be demon-
strated on leucocytes from patients with
untreated acute myeloid leukaemia by
rosetting with homologous (anti-Rhesus)
antibody-coated human Rh+ erythro-
cytes. Leucocytes from a variety ofother
leukaemias, including CML, CLL and
ALL, andlymphoblastoid cell lines, did not
rosette to any significant extent with
HEA. In those cases where rosette
formation occured with anti-D-coated
erythrocytes, there was no evidence that
unsensitized erythrocytes formed spon-
taneous rosettes with these leucocytes,
which distinguishes the present results
from those of a technique of rosette
formation by activated human leucocytes
with unsensitized human 0 Rh-- erythro-
cytes (Sheldon and Holborrow, 1975).
A critical factor in the detection of
leucocytes bearing receptors for Ig, using
the assay described here, is the source of
the anti-Rh serum. We tested 7 different
antisera in the HEA-RFC test with a panel
of normal and AML leucocytes. The
antibody giving the highest rosetting
values with leucocytes from both sources
was an incomplete anti-D (Gm10) typing
serum, though similar values were ob-
tained with anti-CDE and anti-D (Inv').
The anti-D (Gm'0) and the anti-CDE were
the only sera of those tested, carrying the
Gm'I allotype. It is thus significant that
the Gm'0 allotype is restricted to the
IgG3 sub-class (Martensson and Kunkel,
1965) whilst the Gm' and Gm2 allotypes
are restricted to IgGl (Terry, Fahey and
Steinberg, 1965; for review see Grubb,
1970). Other workers have shown that
whilst IgGI and IgG3 are efficient in-
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hibitors, both of the phagocytosis of anti-
body-coated erythrocytes by monocytes
(Huber and Fudenberg, 1968) and HEA
rosetting by lymphocytes, (Fr0land et al.,
1974a), IgGl is much less efficient than
IgG3 in attaching to leucocyte Fc recep-
tors (Abramson et al., 1970b).
We observed quite marked differences
in the capacity ofAML leucocytes to form
rosettes with different types of Rh+
erythrocyte sensitized with the same anti-
Rh antibody. This was particularly the
case when we compared homozygous D
with heterozygous D erythrocytes, or D
homozygous erythrocytes with or without
the presence of C. Rochna and Hughes-
Jones (1965) have shown that cDE/cDE
erythrocytes carry more anti-D combining
sites (25,800-33,300) than CDe/cDE ery-
throcytes (23,000-31,000), the reason being
that the C antigen on the CDe/cDE
erythrocytes reduces the number of avail-
able D antigen combining sites. The
concentration of D antigen combining
sites, and hence the number of Ig mole-
cules attached to the indicator erythro-
cyte, is important in identifying Fc
receptors on leucocytes, according to
Huber et al., (1969) who found that at least
5000 IgG molecules were needed per red
cell to ensure attachment to a majority
(> 900o) ofmonocytes.
In order to study the quantitative
difference between acute myeloid leukae-
mic patients' leucocytes in the HEA-RFC
test, we compared the results with normal
leucocytes. Although the test could prob-
ably be done quite simply on dextran-
separated leucocytes, we thought it im-
portant to establish the number ofnormal
lymphocytes and granulocytes able to
rosette with HEA. The mean HEA-RFC
value for interface leucocytes (11.8%o)
compares well with published values (150,
Fr0land, Wisl0ff and Michaelson, 1974b).
We observed, as have Wisl0ff et al. (1974),
that most of the rosetted cells were
lymphocytic in appearance, when we
examined stained smears ofrosetted inter-
face normal leucocytes. The mean HEA-
RFC value for the sedimented leucocytes
25
(2. 15%) indicatedthatgranulocytes do not
easily rosette, using the assay described
here. Messner and Jelinek (1970), showed
that granulocyte Fc receptors could be
more easily identified using HE coated
with the rare Ripley (anti-CD) serum,
whereas normal anti-D-coated HE de-
tected similar numbers of granulocyte
HEA-RFC to those found here.
The spectrum of cells in the peripheral
blood of acute myeloid leukaemic patients
is far larger than in normal peripheral
blood, and changes in the percentage of
HEA-RFC in AML patients compared
with normal individuals could indicate
either the dilution of normal HEA-RFC
by non-rosetting leukaemic leucocytes
where the HEA-RFC values are low, or
rosette formation by leukaemic cells them-
selves where the HEA-RFC values are
unusually high. Sixteen of the patients
studied had similar or reduced percentages
ofHEA-RFCintheFicoll/Triosil interface,
compared with the normal value, which
can be explained by a dilution effect
brought about by non-rosetting or poorly
rosetting leukaemic blasts. When we
compared these results with the diagnosis
established by independent bone marrow
examination, we found that 10 of the 16
cases were of acute myeloblastic leukae-
mia. Moreover, there was no significant
monoblastic component in the peripheral
blood of these cases. In those of the 16
cases where the numbers of HEA-RFC
were nearer the normal value, but where
there was a high percentage ofmyeloblasts
in the peripheral blood (see Results), it is
likely that a small proportion of the
myeloblasts formed rosettes. Whether
this low percentage is due to the insensi-
tivity of the present method, and its
ability to rosette with myeloblasts, as
appears to be the case for granulocytes, or
whether the assay identifies a sub-popu-
lation of myeloblasts with high-affinity Fe
receptors which cannot be distinguished
from myeloblasts by conventional cyto-
logical staining, requires further study.
In spite of this difficulty with cases of
acute myeloblastic leukaemia, we found
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that nearly one-third of the 22 cases (6)
had conspicuously high HEA-RFC values.
Three out ofthe 6 were also found to have
a high percentage of monoblasts and
promonocytes in the peripheral blood, and
in 2 cases, high numbers of HEA-RFC
were found amongst the sedimented cells.
Of the remaining 3 cases with high levels
of HEA-RFC, none had a significant
monoblastic component. However, retro-
spective comparison with the diagnosis
showed that 5 of the 6 cases were of
myelomonocytic leukaemia, a striking
correlation between the level of peripheral
blood HEA-RFC and the conventional
bone marrow diagnosis. One case presented
a particular diagnostic difficulty, but was
finally called atypical AML with vacuo-
lated promonocytes, though in the peri-
pheral blood we found mainly myeloblast-
looking cells.
Cytocentrifuge preparations of leuco-
cytes from 3 cases ofAMML, 1 ofACMML,
and 1 of smouldering AML, enabled us to
identify HEA-RFC by staining the central
leucocyte in the rosette. RFC found in
the peripheral blood ofthese patients were
either myeloblastic or monoblastic (in-
cluding promonocytes) in appearance.
There is no doubt that other cells may also
form HEA rosettes, particularly those of
the myelocyte series, as indicated by the
smouldering AML. However, the results
in essence show that the HEA-RFC in
acute myeloid leukaemia arerather charac-
teristic ofthe myelomonocytic leukaemias,
as well as the pure monoblastic leukaemias
as observed by Huber et al. (1969).
It is interesting that the present assay
failed to detect the Fc receptors on CLL,
ALL or cell lines. The results for CLL
agree with those of Fr0land et al. (1974b),
but differ from Dickler et al. (1973), who
used aggregated-Ig-binding as their assay
for Fe receptors (Dickler and Kunkel,
1972) and found that most of the CLL
patients had a high percentage of surface
Ig+ aggregated-Ig-binding cells. Fr0land
and Natvig (1973) who have separated
HEA-RFC from B lymphocytes, suggested
that HEA-RFC are different from the
aggregated IgG-binding B cells demon-
strated by Dickler and Kunkel (1972).
Differences in the abilty of aggregated Ig
and antibody-sensitized erythrocytes to
detect Fc receptor cells might explain why
Brown et al. (1974) failed to find any
significant aggregated Ig-binding by leu-
kaemic cells of myeloid origin, whilst we
have demonstrated quite significant num-
bers of HEA-RFC, particularly in the
AMML patients.
The demonstration of Fc receptors on
AML cells is complicated by " blocking
factors" whose removal enhances roset-
ting. Using enzyme concentrations which
had relatively little effect on rosetting by
normal lymphocytes (except papain), con-
spicuous increases in HEA-RFC were seen
in a number of (though not all) AML
leucocyte preparations, particularly when
treated with pronase. Unsensitized HE
showed no tendency to bind to enzyme-
treated AML cells, neither could rosetting
be detected by cell lines treated with
proteolytic enzymes. The results show
that pronase treatment removes " block-
ing factor" when it occurs, and destroys
Fc receptors where the blocking factor
does not occur. The pronase sensitivity
of lymphocyte Fc receptors was noted by
Dickler (1974) who suggested that Fc
receptors per se, or their attachment to the
cell surface, are protein or glycoprotein
in nature.
HEA rosette formation by AML and
normal lymphocytes was strongly in-
hibited by normal AB and AML serum
and by Cohn Fraction II human y-
globulin, but less or not at all by Cohn
Fraction V human albumin. This evi-
dence shows that " blocking factor " is
found both in normal and AML sera, and
may be Ig, though whether it is complexed
with an antigen is not yet known. Several
authors have shown that Fc receptors on
monocytes or lymphocytes can be blocked
by homologous Ig, its sub-classes or
fragments produced by enzyme digestion.
Thus, Huber and Fudenberg (1968) found
that pooled IgG or IgGi or IgG3 had a
strongly inhibitory effect oIn monocyte
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phagocytosis, whereas IgG2 and IgG4
were less effective. Very similar results
were obtained by Abramson et al. (1970b),
who showed in addition that Fc fragments
and y-1 and y-3 H-chains inhibited roset-
ting by leucocytes, whilst y-4 H-chain was
less inhibitory, and Fab, F(ab')2 and
albumin were almost non-inhibitory.
Other authors (Messner and Jelinek,
1970, Fr0land et al., 1974a) have observed
similar inhibition of HEA-RFC, but
Dickler and Kunkel (1972) were unable to
inhibit aggregated Ig binding of normal
lymphocytes by pre-incubation with IgG,
further evidence for a difference between
the HEA and aggregated Ig-binding assays
for Fc receptors.
The removal of " blocking factor " by
pronase treatment was found to increase
the proportions of RFC+Ig+, or RFC+Ig-
cells and decrease the proportion of
RFC-Ig+ cells. This could be explained
by the removal ofIgG by pronase digestion
leading to the exposure of Fc receptors.
If this is the case, then the Ig-blocking Fc
receptors on AML leucocytes must be
tightly bound, since they are not removed
by normal cell-washing procedures. The
presence of characteristic surface Ig on
AML cells has previously been documented
by Gutterman et al. (1973). It is not yet
clear whether this Ig consists entirely of
normal Ig aggregates or immune com-
plexes, perhaps including viral antigens,
and what proportion of it is bound to Fc
receptors. There is also a possibility that
some of the Fe receptor-bound Ig shows
antibody activity to Fc receptors similar
to that capable of inhibiting aggregated
Ig-binding by B lymphocyte receptors in
mice (Dickler and Sachs, 1974).
This study has shown that cells identi-
fied morphologically as myeloblasts and
monoblasts have Fc receptors, though we
conclude that myeloblasts in patients with
acute myeloblastic leukaemia may not be
as efficient in rosetting as myeloblasts in
AMML patients. The myeloblasts in
acute myeloblastic and acute myelomono-
cytic leukaemia may thus differ in their
expression or exposure of Fc receptors as
identified in the HEA-RFC assay. Never-
theless, the good correlation of the results
with the bone marrow diagnosis supports
the contention that the HEA-RFC assay
could be used to diagnose AMML cases
using peripheral blood leucocytes.
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